NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Pluri Inc. (PLUR) Stock Analysis

Pluri Inc. (PLUR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

PLUR

$1.05

+$0.15 (+16.67%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PLUR with… →

PLUR Key Statistics

As of Oct 21, 2026
Trading
Open
$1.00
Previous Close
$0.90
Day's Range
0.91–1.08
52-Week Range
0.85–4.87
Volume
50.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.69
Valuation
Market Cap
$13.24M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
13.03
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.44
Financials (FY)
Revenue (FY)
$1.34M+309.82%
Net Income (FY)
−$22.58M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
12.61M
1-Year Return
−74.33%
Dividend and dates
Avg Volume
20.13K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, PLUR closed at $1.05, −74.33% over 1 year.

Pluri Inc. (PLUR) has a market capitalization of $13.24M.

In fiscal 2025, PLUR reported revenue of $1.34M.

PLUR Stock Return by Calendar Year

Pluri Inc. (PLUR) 10-year return: what $10,000 became

1 year
$10,000 $2,567
−74.33%
5 years
$10,000 $439
−95.61%
10 years
$10,000 $86
−99.14%

If you had invested $10,000 in Pluri Inc. (PLUR) 10 years ago, at the close on October 21, 2016, it would have been worth $86 at the close on October 21, 2026: −99.14% in total, −37.86% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−64.88%
2025−30.14%
2024−7.76%
2023−38.30%
2022−35.62%
2021−79.35%
2020+79.44%
2019−50.13%
2018−42.75%
2017−3.50%
2016 (partial year)−6.54%

As of October 21, 2026.

PLUR Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2025$1.34M−$22.58M−1,690.3%
2024$326.00K−$20.89M−6,407.4%
2023$287.00K−$28.32M−9,867.9%
2022$234.00K−$41.24M−17,624.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.34M$654.00K−$22.18M−$22.58M−1,690.3%
2024$326.00K$322.00K−$22.16M−$20.89M−6,407.4%
2023$287.00K$278.00K−$27.25M−$28.32M−9,867.9%
2022$234.00K$234.00K−$41.59M−$41.24M−17,624.8%

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

PLUR Valuation vs Biotechnology Median

Median of 608 stocks
MetricPLURBiotechnology medianvs median
P/S ratio13.0313.302% below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Pluri Inc. (PLUR) at $13.24M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 92 employees.

Over the past 52 weeks the price has ranged from $0.85 to $4.87. PLUR last closed at $1.05 on October 21, 2026. That is +$0.15 (+16.67%) against the previous close. The latest close sits 23.53% above that 52-week low.

Financial Health

In fiscal 2025, Pluri Inc. reported revenue of $1.34M. Against the prior fiscal year total of $326.00K, that is a change of +309.82%. The same year closed with a net loss of $22.58M. Earnings per share on a trailing basis come to −2.44.

Across the 4 fiscal years on file, revenue moves from $234.00K in 2022 to $1.34M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 13.03 times revenue. On price-to-sales that is 1.99% below the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.69. Annualized volatility over the trailing 10 years is 74.41%. The trailing one-year total return is −74.33%. Across 10 years the annualized return works out at −37.86%.

Growth & Income

The record shows no dividend for PLUR.

The strongest complete calendar year on file is 2020 at +79.44%; the weakest is 2021 at −79.35%. Of the 9 complete calendar years on file, 1 finished higher. So far in 2026 the total return is −64.88%.

Peer Comparison

Pluri Inc. (PLUR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Pluri Inc. PLUR $13.24M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Pluri Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Pluri Inc.

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform. Its product candidates include PLX-PAD, which is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. The company also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. It operates in the field of regenerative medicine, food tech, immunotherapy, as well as contract development and manufacturing organization (CDMO) services for pharmaceutical and biotechnology companies under the PluriCDMO division, and AgTech. It has a collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Visit website →